EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
+0.10 (0.59%)
Real-time:   2:20PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.95 - 17.50
52 week 4.67 - 25.00
Open 16.00
Vol / Avg. 14.62M/8.31M
Mkt cap 1.73B
P/E     -
Div/yield     -
EPS -1.81
Shares 98.33M
Beta 0.99
Inst. own 84%
Jul 28, 2016
Exact Sciences Corp Annual Shareholders Meeting - Webcast
Jul 26, 2016
Q2 2016 Exact Sciences Corp Earnings Call - Webcast
Jul 26, 2016
Q2 2016 Exact Sciences Corp Earnings Release
Jul 22, 2016
Exact Sciences Corp Annual Shareholders Meeting (Estimated)
Jun 15, 2016
Exact Sciences Corp at William Blair Growth Stock Conference
Jun 9, 2016
Exact Sciences Corp at Jefferies Healthcare Conference
Jun 8, 2016
Exact Sciences Corp at Goldman Sachs Global Healthcare Conference
May 24, 2016
Exact Sciences Corp at UBS Global Healthcare Conference
May 11, 2016
Exact Sciences Corp at Bank of America Merrill Lynch Health Care Conference
May 3, 2016
Q1 2016 Exact Sciences Corp Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -211.31% -400.14%
Operating margin -213.06% -403.35%
EBITD margin - -383.70%
Return on average assets -58.65% -46.63%
Return on average equity -66.78% -51.25%
Employees 677 -
CDP Score - -


441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company's product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
John K. Bakewell Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
William J. Megan Senior Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Graham Peter Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
John A. Fallon M.D. Director
Age: 68
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 53
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 64
Bio & Compensation  - Reuters